WASHINGTON — A tiny biosimilar company called Coherus Biosciences is emerging as one of the loudest critics of President Trump’s plan to tie what the U.S. pays for pricey injectable drugs to what other countries pay.
In the three weeks since the Trump administration unveiled the controversial policy, the company has had roughly a dozen conversations with Trump administration officials, inserted itself into the ongoing lawsuit against the policy filed by the Biotechnology Innovation Organization, and already filed sharply worded comments on the regulation — six weeks ahead of the official deadline.
All of this action comes from a company with just one registered in-house lobbyist and two outside lobbying firms. Pharmaceutical behemoths, like Amgen and Genentech, have been taking similar actions, but they have more money at stake, and far more resources in Washington. For comparison: Amgen has 10 in-house lobbyists and 24 outside firms on retainer.